ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer
Crizotinib and entrectinib are both active against ROS1 non-small cell lung cancer. But which is…
Browsing: “virtual” clinical trial
Crizotinib and entrectinib are both active against ROS1 non-small cell lung cancer. But which is…